Reports Q2 revenue $26.4M, consensus $25.7M. “We are pleased to report continued momentum across our portfolio of partnered assets, with multiple positive developments for our commercial and pipeline products,” said Todd Davis, CEO of Ligand. “Ligand has a strong balance sheet with $219 million in cash, and, after a recent paydown of convertible notes, we are debt free with positive cash flows that can also be deployed. We are well positioned to make additional investments, that, paired with our enhanced deal skillset and expanded team, are expected to add robust programs and diversity to our product pipeline.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LGND:
- Is LGND a Buy, Before Earnings?
- Ligand says Merck reports V116 met key endpoints in two Phase 3 trials
- Ligand price target lowered to $110 from $120 at Barclays
- Ligand offers to acquire Novan for $15M in cash, $15M in financing
- Novan to sell substantially all assets for $15M, files for Chapter 11 protection